Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$10.18 - $26.64 $2.81 Million - $7.34 Million
-275,567 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$18.57 - $35.68 $17,752 - $34,110
956 Added 0.35%
275,567 $7.34 Million
Q1 2021

May 14, 2021

SELL
$31.0 - $55.72 $176,607 - $317,436
-5,697 Reduced 2.03%
274,611 $9.53 Million
Q4 2020

Feb 12, 2021

SELL
$37.09 - $48.97 $160,748 - $212,235
-4,334 Reduced 1.52%
280,308 $10.4 Million
Q3 2020

Nov 13, 2020

SELL
$40.47 - $45.5 $658,082 - $739,875
-16,261 Reduced 5.4%
284,642 $11.7 Million
Q2 2020

Aug 13, 2020

BUY
$32.57 - $42.83 $4 Million - $5.26 Million
122,706 Added 68.86%
300,903 $12.2 Million
Q1 2020

May 14, 2020

SELL
$23.3 - $45.96 $109,440 - $215,874
-4,697 Reduced 2.57%
178,197 $6.19 Million
Q4 2019

Feb 12, 2020

BUY
$34.58 - $48.06 $3.34 Million - $4.65 Million
96,661 Added 112.09%
182,894 $7.84 Million
Q3 2019

Nov 13, 2019

BUY
$36.98 - $48.45 $188,708 - $247,240
5,103 Added 6.29%
86,233 $3.19 Million
Q2 2019

Aug 14, 2019

SELL
$35.13 - $55.53 $7,201 - $11,383
-205 Reduced 0.25%
81,130 $3.67 Million
Q1 2019

May 14, 2019

SELL
$42.83 - $59.91 $404,229 - $565,430
-9,438 Reduced 10.4%
81,335 $0
Q4 2018

Feb 13, 2019

BUY
$37.97 - $60.16 $45,753 - $72,492
1,205 Added 1.35%
90,773 $4.2 Million
Q3 2018

Nov 02, 2018

SELL
$56.3 - $67.25 $36,538 - $43,645
-649 Reduced 0.72%
89,568 $5.44 Million
Q2 2018

Aug 08, 2018

BUY
$44.9 - $64.95 $236,533 - $342,156
5,268 Added 6.2%
90,217 $5.65 Million
Q1 2018

May 03, 2018

BUY
$45.35 - $61.65 $58,682 - $79,775
1,294 Added 1.55%
84,949 $3.93 Million
Q4 2017

Feb 02, 2018

BUY
$41.95 - $60.1 $976,889 - $1.4 Million
23,287 Added 38.58%
83,655 $3.97 Million
Q3 2017

Nov 01, 2017

BUY
$33.4 - $53.9 $2.02 Million - $3.25 Million
60,368
60,368 $3.25 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $54.4M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.